miércoles, 25 de noviembre de 2009

The Worst Drug Company Marketing Techniques (VI): GLAXO

After the Internal Revenue Service accused GlaxoSmithKline of more than a decade of underpaid taxes, the British drug company agreed in 2006 to pay the IRS a record $3.4 billion. And earlier this year, GSK said it would pay $400 million to resolve allegations that it marketed its drugs -- namely the antidepressant Wellbutrin -- for off-label use.

Ver anteriores...

No hay comentarios: